Preventing low white blood cell counts in kids with solid tumors
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like bone or muscle cancer) that needs strong chemotherapy.
- You have had at least 2 more rounds of chemo planned.
- In your last chemo round, you had a fever with low white blood cells (febrile neutropenia) or very low white blood cells that forced a change in your treatment.
- You are between 6 and 24 years old.
- You are generally well enough to do light activities (like walking or playing) without help.
- Your blood counts (red cells, white cells, platelets) are high enough to start a new chemo cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
This Phase 1/2 study tests whether donated white blood cells (granulocytes) from healthy donors can help treat solid cancers that cannot be cured or have stopped responding to standard treatments. The goal is to see safety first, and then whether the treatment can shrink or control tumors.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.